Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET-Reference-Cited by-同舟云学术

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET

Published:2008-06 Issue:6 Volume:29 Page:521-526
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Berkowitz Arnold,Basu Sandip,Srinivas Shyam,Sankaran Shrinkanthan,Schuster Stephen,Alavi Abass

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference18 articles.

1. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer;Choi;Ann Nucl Med,2005

2. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding;Erdi;Cancer,1997

3. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators;Alavi;J Nucl Med,1993

4. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept;Bural;Nucl Med Biol,2006

5. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis;Larson;Clin Positron Imaging,1999

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lesion Analysis in PERCIST 1.0: Clinical Ease versus Research Requisite—Where Does the Balance Exist?;World Journal of Nuclear Medicine;2023-04-28

2. The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19;The European Physical Journal Plus;2023-03-27

3. FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?;Molecular Imaging and Biology;2022-04-29

4. Potential and Most Relevant Applications of Total Body PET/CT Imaging;Clinical Nuclear Medicine;2022-01

5. Artificial Intelligence in Lymphoma PET Imaging;PET Clinics;2022-01